RxDoctor Payments Data

David Truitte, MD

Cardiovascular Disease · Lynchburg, VANPI 1518941913

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Impulse Dynamics (USA) Inc. at 41.6% of the total. Reporting peaked in 2022 at $63 and has fallen 64.6% since, to $22 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in VA, where the typical reported total is $1,293.

$151in general payments, 2019–2025

Across 6 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$63
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$39
  • Novartis$26
  • Astellas Pharma US Inc$24
$325in research payments, 2019–2025

Across 1 payment — averaging $325.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$325

What the payments were for

  • Food & beverage$151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$151 in reported general payments places this provider in the 15th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$182,693
Medicare patients
2,418
Services billed
3,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$90,171
EntrestoSacubitril/Valsartan77$53,765
Repatha SureclickEvolocumab33$23,573
XareltoRivaroxaban30$21,662
Metoprolol Succinate98$1,063
Carvedilol137$776
Atorvastatin Calcium83$550
Torsemide23$509
Rosuvastatin Calcium69$497
ClopidogrelClopidogrel Bisulfate41$487
Losartan Potassium29$433
Chlorthalidone12$330
Amlodipine Besylate86$317
Metoprolol Tartrate62$247
Lisinopril33$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$26$53,76577 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →